Activating EZH2 mutations may define a new subset of aggressive Ewing sarcomas that benefit from treatment with an EZH2 inhibitor  

Molecular genetic analyses of NETs hint at actionable therapeutic targets and potential predictive biomarkers of response to axitinib 

Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target 

Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments 

CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies  

An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions 

Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression 

Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy 

Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights 

Adoption of molecular-based early detection techniques in clinical practice depends on the success of large-scale clinical studies and cost barriers